Literature DB >> 18321578

Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis.

J Wayne Conlan1, Xigeng Zhao, Gregory Harris, Hua Shen, Mark Bolanowski, Cecilia Rietz, Anders Sjostedt, Wangxue Chen.   

Abstract

The type A subspecies of Francisella tularensis is a highly virulent facultative intracellular bacterial pathogen, and a potential biological weapon. Recently, there has been renewed interest in developing new vaccines and therapeutics against this bacterium. Natural cases of disease, tularemia, caused by the type A subspecies are very rare. Therefore, the United States Food and Drug Administration will rely on the so-called Animal Rule for efficacy testing of anti-Francisella medicines. This requires the human disease to be modeled in one or more animal species in which the pathogenicity of the agent is reasonably well understood. Mice are natural hosts for F. tularensis, and might be able to satisfy this requirement. Tularemia pathogenesis appears to be primarily due to the host inflammatory response which is poorly understood at the molecular level. Additionally, the extent to which this response varies depending on host and pathogen genetic background, or by pathogen challenge route or dose is unknown. Therefore, the present study examined sera and infected tissues from C57BL/6 and BALB/c mice challenged by natural intradermal (ID) and respiratory routes with one of two distinct type A strains of the pathogen for cytokine and chemokine responses that might help to explain the morbidity associated with tularemia. The results show that the molecular immune response was mostly similar regardless of the variables examined. For instance, mRNA for the proinflammatory cytokine IL-6, and chemokines KC, and IP-10 was consistently upregulated at all sites of infection. Upregulation of mRNA for several other cytokines and chemokines occurred in a more tissue restricted manner. For instance, IFN-gamma was highly upregulated in the skin of BALB/c, but not C57BL/6 mice after ID inoculation of the pathogen, whilst IL-10 mRNA upregulation was only consistently seen in the skin and lungs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321578      PMCID: PMC2715917          DOI: 10.1016/j.molimm.2008.01.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  23 in total

Review 1.  2. Cytokines and chemokines.

Authors:  Larry C Borish; John W Steinke
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

Review 2.  Chemokine receptors and their role in inflammation and infectious diseases.

Authors:  C Murdoch; A Finn
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

3.  Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.

Authors:  J Wayne Conlan; Hua Shen; Ann Webb; Malcolm B Perry
Journal:  Vaccine       Date:  2002-10-04       Impact factor: 3.641

4.  Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.

Authors:  M Fulop; P Mastroeni; M Green; R W Titball
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

5.  The pathology of untreated and antibiotic-treated experimental tularaemia in monkeys.

Authors:  A Baskerville; P Hambleton; A B Dowsett
Journal:  Br J Exp Pathol       Date:  1978-12

6.  Pathogenesis and pathology of respiratory tularaemia in the rabbit.

Authors:  A Baskerville; P Hambleton
Journal:  Br J Exp Pathol       Date:  1976-06

7.  Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen.

Authors:  Hua Shen; Wangxue Chen; J Wayne Conlan
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

Review 8.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

Review 9.  Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain.

Authors:  Karen L Elkins; Siobhán C Cowley; Catharine M Bosio
Journal:  Microbes Infect       Date:  2003-02       Impact factor: 2.700

10.  Fibrin-mediated protection against infection-stimulated immunopathology.

Authors:  Lawrence L Johnson; Kiera N Berggren; Frank M Szaba; Wangxue Chen; Stephen T Smiley
Journal:  J Exp Med       Date:  2003-03-10       Impact factor: 14.307

View more
  25 in total

1.  Significance analysis of xMap cytokine bead arrays.

Authors:  Joong-Ho Won; Ofir Goldberger; Shai S Shen-Orr; Mark M Davis; Richard A Olshen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-09       Impact factor: 11.205

2.  Detrimental Influence of Alveolar Macrophages on Protective Humoral Immunity during Francisella tularensis SchuS4 Pulmonary Infection.

Authors:  Donald J Steiner; Yoichi Furuya; Dennis W Metzger
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

3.  IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis.

Authors:  Timothy J Bauler; Jennifer C Chase; Catharine M Bosio
Journal:  J Immunol       Date:  2011-07-13       Impact factor: 5.422

Review 4.  Targeting the "cytokine storm" for therapeutic benefit.

Authors:  Riccardo V D'Elia; Kate Harrison; Petra C Oyston; Roman A Lukaszewski; Graeme C Clark
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

5.  Features of sepsis caused by pulmonary infection with Francisella tularensis Type A strain.

Authors:  Jyotika Sharma; Chris A Mares; Qun Li; Elizabeth G Morris; Judy M Teale
Journal:  Microb Pathog       Date:  2011-04-01       Impact factor: 3.738

6.  Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Authors:  J Wayne Conlan; Hua Shen; Igor Golovliov; Carl Zingmark; Petra C F Oyston; Wangxue Chen; Robert V House; Anders Sjöstedt
Journal:  Vaccine       Date:  2009-12-16       Impact factor: 3.641

7.  Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.

Authors:  Joshua D Hall; Matthew D Woolard; Bronwyn M Gunn; Robin R Craven; Sharon Taft-Benz; Jeffrey A Frelinger; Thomas H Kawula
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

8.  Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).

Authors:  Susan M Twine; Mireille D Petit; Kelly M Fulton; Robert V House; J Wayne Conlan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

9.  Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.

Authors:  Hua Shen; Gregory Harris; Wangxue Chen; Anders Sjostedt; Patrik Ryden; Wayne Conlan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

10.  Host immune response and acute disease in a zebrafish model of Francisella pathogenesis.

Authors:  Lucia N Vojtech; George E Sanders; Carla Conway; Vaughn Ostland; John D Hansen
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.